Bariatric Surgery PatientsTEAM-EDNCT06914219
Implementing an Interdisciplinary Eating Disorder Screening and Treatment Program for Post-Bariatric Surgery Patients in Nova Scotia
A study testing Treatment and Evaluation for After Metabolic Surgery with Eating Disorders (TEAM-ED) Program in people with Bariatric Surgery Patients and Disordered Eating Behaviors, run by Aaron Keshen at 1 site in Canada.
Trial summary
The goal of this interventional study is to evaluate the Treatment and Evaluation for After Metabolic Surgery with Eating Disorders (TEAM-ED) program, which combines streamlined access to screening, diagnostic assessment, and treatment with an interdisciplinary team approach to treatment planning, for managing… Read more about this study
- Who is it for?
- Ages 19 years and older
- Conditions the study is for
- Bariatric Surgery Patients, Disordered Eating Behaviors
- What is being tested?
- Treatment and Evaluation for After Metabolic Surgery with Eating Disorders (TEAM-ED) Program
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 250 participants
- Where
- 1 siteCanada
- Study dates
- 4 Mar 2026to May 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- ≥19 years old
- Between 3- and 18-months post-weight loss surgery.
- Able to complete English computer-based self-report questionnaires (with adequate accommodation, if necessary).
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Canada1 site, 1 recruiting
- Recruiting
Abbie J Lane Memorial Building, QEII Health Sciences Centre, Nova Scotia Health Authority
Halifax, Nova Scotia, B3H 2E2
Aaron Keshen, MD, 902-449-8228, aaron.keshen@nshealth.ca
About this study
The goal of this interventional study is to evaluate the Treatment and Evaluation for After Metabolic Surgery with Eating Disorders (TEAM-ED) program, which combines streamlined access to screening, diagnostic assessment, and treatment with an interdisciplinary team approach to treatment planning, for managing disordered eating in adults who have recently had weight loss surgery in Nova Scotia. The main question it aims to answer is 'can an interdisciplinary program for identifying and managing disordered eating after weight loss surgery be implemented in Nova Scotia?
This study will determine the feasibility and impact of the TEAM-ED program by assessing the following objectives:
Read more
- Reach (how effectively the program engages the target population [post-weight loss surgery patients])
- Effectiveness (the extent of the program's impact on key clinical outcomes related to disordered eating and weight management)
- Adoption (the extent to which the program is adopted and accepted by clinicians)
- Implementation (how consistent program delivery is and factors impacting consistent delivery)
Participants will complete a disordered eating screening questionnaire online every 3 months after weight loss surgery until they reach 18-months post-surgery. Participants found to have disordered eating will be referred to the Nova Scotia Provincial Eating Disorder Service (NSEDPS) for standard disordered eating treatment (brief cognitive behavioral therapy [CBT-T]) plus treatment plan oversight by both weight loss surgery and eating disorder specialists. Standard outcome measures will be collected at baseline, during eating disorder treatment, post-treatment, and at follow-ups. Participants may also be asked to do a one-on-one research interview about their experiences with the program.
- Being tested
- Treatment and Evaluation for After Metabolic Surgery with Eating Disorders (TEAM-ED) Program
- Medical subject headings
- Disordered Eating Behavior
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Treatment and Evaluation for After Metabolic Surgery with Eating Disorders (TEAM-ED) ProgramBehavioural
A program that combines a) streamlined access to screening, diagnostic assessment, and treatment (brief cognitive behaviour therapy [CBT-T]), b) an interdisciplinary team approach to treatment planning, for managing disordered eating in patients post-weight loss surgery.
| Study group | Role | What they receive |
|---|---|---|
| TEAM-ED Program | Experimental | Not described Receives: Behavioral: Treatment and Evaluation for After Metabolic Surgery with Eating Disorders (TEAM-ED) Program |
What is being measured
The primary outcome is the main question the study is designed to answer.
Screening Engagement Rate
Percentage of eligible patients (i.e., post-weight loss patients who are enrolled in the screening procedure) who complete the disordered eating screening measure (i.e., Loss of Control Over Eating Scale [LOCES]) at each timepoint (3-, 6-, 9-, 12-, 15-, and 18-month). To be calculated with the equation: [Actual # of LOCES completed at a timepoint] / [Total # of eligible patients who could have completed LOCES at that timepoint]
Measured: From the post-weight loss surgery timepoint when a participant is first enrolled in the screening procedure (3-, 6-, 9-, 12-, 15-, or 18-months) until 18-months post-surgery or until they screen positive for disordered eating.
Secondary outcomes (32)
Screening Initiation Rate
Percentage of eligible patients (i.e., those who are 3- to 18-months post-weight loss surgery and receiving follow-up care at the study clinics) who initiate the screening procedure. This will be calculated using the equation: [number of patients who fill out their initial screening questionnaire] / [number of patients registered for follow-up care post-weight loss surgery at the study clinics]. *Screening questionnaire is the Loss of Control Over Eating Scale (LOCES).
Measured: From 3- to 18-months post-weight loss surgery.
Proportion of eligible patients who screen positive for loss of control eating.
Proportion of eligible patients (i.e., those enrolled in the screening procedure) who are identified via screening questionnaire as having loss of control eating. This will be calculated using the equation: [number of patients who screen positive for loss of control eating] / [number of patients enrolled in screening procedure]. *Screening questionnaire is the Loss of Control Over Eating Scale (LOCES).
Measured: From 3- to 18-months post-weight loss surgery.
Proportion of eligible patients who undergo a disordered eating diagnostic interview.
Proportion of eligible patients (i.e., those who screen positive for disordered eating) who complete a disordered eating diagnostic interview led by a clinician using the Eating Disorder Examination - Bariatric Surgery Version (EDE-BSV).
Measured: From the post-weight loss surgery timepoint when a participant is first enrolled in the screening procedure (3-, 6-, 9-, 12-, 15-, or 18-months) until they screen positive for disordered eating.
Proportion of eligible patients who are diagnosed with disordered eating.
Proportion of eligible patients (i.e., those in the screening procedure who screen positive then attend a disordered eating diagnostic interview) who are diagnosed with disordered eating by the clinician conducting the interview based on the results of that assessment.
Measured: From the post-weight loss surgery timepoint when a participant is first enrolled in the screening procedure (3-, 6-, 9-, 12-, 15-, or 18-months) until they screen positive for disordered eating.
Proportion of eligible patients who start disordered eating treatment.
Proportion of eligible patients (i.e., those diagnosed with disordered eating following diagnostic interview) who choose to start treatment for disordered eating.
Measured: From the post-weight loss surgery timepoint when a participant is first enrolled in the screening procedure (3-, 6-, 9-, 12-, 15-, or 18-months) until they screen positive for disordered eating.
Change in disordered eating symptom frequency from baseline to post-treatment.
Patients in TEAM-ED treatment will complete the Eating Disorder Examination Questionnaire (EDE-Q) before and after the core sessions of brief cognitive behavior therapy (i.e., Week 10).
Measured: From baseline to post-treatment (Week 10).
Change in disordered eating psychopathology severity from baseline to Week 4.
Patients in TEAM-ED treatment will complete the Eating Disorder Examination Questionnaire (EDE-Q) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. EDE-Q global scores range from 0-6, with higher scores indicating increased severity of eating disorder psychopathology.
Measured: From baseline to Week 4.
Change in disordered eating psychopathology severity from baseline to post-treatment (Week 10).
Patients in TEAM-ED treatment will complete the Eating Disorder Examination Questionnaire (EDE-Q) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. EDE-Q global scores range from 0-6, with higher scores indicating increased severity of eating disorder psychopathology.
Measured: From baseline to post-treatment (Week 10).
Change in disordered eating psychopathology severity from baseline to 1-month follow-up.
Patients in TEAM-ED treatment will complete the Eating Disorder Examination Questionnaire (EDE-Q) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. EDE-Q global scores range from 0-6, with higher scores indicating increased severity of eating disorder psychopathology.
Measured: From baseline to 1-month follow-up (i.e., 1 month after Week 10).
Change in disordered eating psychopathology severity from baseline to 3-month follow-up.
Patients in TEAM-ED treatment will complete the Eating Disorder Examination Questionnaire (EDE-Q) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. EDE-Q global scores range from 0-6, with higher scores indicating increased severity of eating disorder psychopathology.
Measured: From baseline to 3-month follow-up (i.e., 3 months after Week 10).
Change in anxiety symptom severity from baseline to Week 4.
Patients in TEAM-ED treatment will complete the Generalized Anxiety Disorder Scale (GAD-7) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. GAD-7 total scores range from 0 to 21, with higher scores indicating greater severity of generalized anxiety symptoms.
Measured: From baseline to Week 4.
Change in anxiety symptom severity from baseline to post-treatment (Week 10).
Patients in TEAM-ED treatment will complete the Generalized Anxiety Disorder Scale (GAD-7) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. GAD-7 total scores range from 0 to 21, with higher scores indicating greater severity of generalized anxiety symptoms.
Measured: From baseline to post-treatment (Week 10).
Change in anxiety symptom severity from baseline to 1-month follow-up.
Patients in TEAM-ED treatment will complete the Generalized Anxiety Disorder Scale (GAD-7) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. GAD-7 total scores range from 0 to 21, with higher scores indicating greater severity of generalized anxiety symptoms.
Measured: From baseline to 1-month follow-up (i.e., 1 month after Week 10).
Change in anxiety symptom severity from baseline to 3-month follow-up.
Patients in TEAM-ED treatment will complete the Generalized Anxiety Disorder Scale (GAD-7) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. GAD-7 total scores range from 0 to 21, with higher scores indicating greater severity of generalized anxiety symptoms.
Measured: From baseline to 3-month follow-up (i.e., 3 months after Week 10).
Change in depression symptom severity from baseline to Week 4.
Patients in TEAM-ED treatment will complete the Patient Health Questionnaire (PHQ-9) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. PHQ-9 total scores range from 0 to 27, with higher scores indicating greater severity of depressive symptoms.
Measured: From baseline to Week 4.
Change in depression symptom severity from baseline to post-treatment (Week 10).
Patients in TEAM-ED treatment will complete the Patient Health Questionnaire (PHQ-9) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. PHQ-9 total scores range from 0 to 27, with higher scores indicating greater severity of depressive symptoms.
Measured: From baseline to post-treatment (Week 10).
Change in depression symptom severity from baseline to 1-month follow-up.
Patients in TEAM-ED treatment will complete the Patient Health Questionnaire (PHQ-9) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. PHQ-9 total scores range from 0 to 27, with higher scores indicating greater severity of depressive symptoms.
Measured: From baseline to 1-month follow-up (i.e., 1 month after Week 10).
Change in depression symptom severity from baseline to 3-month follow-up.
Patients in TEAM-ED treatment will complete the Patient Health Questionnaire (PHQ-9) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. PHQ-9 total scores range from 0 to 27, with higher scores indicating greater severity of depressive symptoms.
Measured: From baseline to 3-month follow-up (i.e., 3 months after Week 10).
Change in psychosocial impairment from baseline to Week 4.
Patients in TEAM-ED treatment will complete the Clinical Impairment Assessment (CIA) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. CIA total scores range from 0 to 48, with higher scores indicating greater psychosocial impairment due to eating disorder symptoms.
Measured: From baseline to Week 4.
Change in psychosocial impairment from baseline to post-treatment (Week 10).
Patients in TEAM-ED treatment will complete the Clinical Impairment Assessment (CIA) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. CIA total scores range from 0 to 48, higher scores indicating greater psychosocial impairment due to eating disorder symptoms.
Measured: From baseline to post-treatment (Week 10).
Change in psychosocial impairment from baseline to 1-month follow-up.
Patients in TEAM-ED treatment will complete the Clinical Impairment Assessment (CIA) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. CIA total scores range from 0 to 48, higher scores indicating greater psychosocial impairment due to eating disorder symptoms.
Measured: From baseline to 1-month follow-up (i.e., 1 month after Week 10).
Change in psychosocial impairment from baseline to 3-month follow-up.
Patients in TEAM-ED treatment will complete the Clinical Impairment Assessment (CIA) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. CIA total scores range from 0 to 48, higher scores indicating greater psychosocial impairment due to eating disorder symptoms.
Measured: From baseline to 3-month follow-up (i.e., 3 months after Week 10).
Change in weight from baseline to Week 4.
Patient weight as measured with a standard scale.
Measured: From baseline to Week 4.
Change in weight from baseline to post-treatment (Week 10).
Patient weight as measured with a standard scale.
Measured: From baseline to post-treatment (Week 10).
Change in weight from baseline to 1-month follow-up.
Patient weight as measured with a standard scale.
Measured: From baseline to 1-month follow-up (i.e., 1 month after Week 10).
Change in weight from baseline to 3-month follow-up.
Patient weight as measured with a standard scale.
Measured: From baseline to 3-month follow-up (i.e., 3 months after Week 10).
Treatment Non-Response Rate
Percentage of eligible patients (i.e., those who start disordered eating treatment) who are deemed as not progressing in therapy as expected (per the CBT-T treatment manual, as determined by the clinician conducting their sessions). To be calculated with the equation: [# of patients who start CBT-T] / [# of patients deemed 'non-responders' by their clinician.]
Measured: From baseline (Week 1) to post-treatment (Week 10).
Treatment Completion Rate
Percentage of eligible patients (i.e., those who start disordered eating treatment) who complete the core treatment (i.e., 10 weekly sessions) and that complete core treatment plus follow-ups (i.e., 1- and 3-month sessions). To be calculated with the equation: [# of patients who start CBT-T] / [# of patients recorded as having completed their prescribed course of treatment by their clinician.]
Measured: From baseline to 3-month follow-up (i.e., 3 months after Week 10)
Program Dropout Rate
Percentage of eligible patients (i.e., those who initiate the screening procedure) who dropout of the TEAM-ED program.
Measured: From recruitment initiation (Month 0) to recruitment end (Month 24).
Acceptability of the TEAM-ED program to clinicians.
Clinicians engaged in the TEAM-ED program will be asked to complete a survey online at ~12 and 18 months into the study (i.e., following the start of recruitment). The objectives of these groups is to: Evaluate the interdisciplinary approach; Identify barriers and facilitators; Assess the perceived effectiveness; and Refine and optimize the model.
Measured: At 12 and 18 months.
Adjunctive Pharmacotherapy Initiation Rate
Percentage of eligible patients (i.e., those who start disordered eating treatment) who initiate pharmacotherapy for related symptoms during their course of treatment. *This variable is observational - pharmacotherapy initiation is not being directed or controlled by the research protocol or research team.
Measured: From baseline to 3-month follow-up.
Patient satisfaction with the TEAM-ED program.
Patients in TEAM-ED treatment will participate in a semi-structured, one-on-one interview with a trained research assistant. The objectives of the interviews are to assess overall patient satisfaction with the program including strengths and weaknesses, perceived effectiveness, and areas requiring refinement.
Measured: At 3-month follow-up (i.e., 3 months after Week 10).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Apr 2025
- Study start4 Mar 2026
- Primary completionMay 2027 (estimated)
- Study completionMay 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Bariatric Surgery PatientsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 250 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Aaron Keshen
- Sponsor type
- University, hospital or other
- Collaborators
- Queen Elizabeth II Health Sciences Centre Foundation
- Responsible party
- Sponsor-investigator, Aaron Keshen, Nova Scotia Health Authority
- Investigators
- Aaron Keshen, MD, Principal investigator, Nova Scotia Health Authority
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06914219
- Sponsor's protocol ID
- TEAM-ED
- Acronym
- TEAM-ED
- Status last verified
- Oct 2026
- First submitted
- 31 Mar 2025
- Last updated
- 20 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Implementing an Interdisciplinary Eating Disorder Screening and Treatment Program for Post-Bariatric Surgery Patients in Nova Scotia
- ClinicalTrials.gov ID
- NCT06914219
- Acronym / sponsor ID
- TEAM-ED / TEAM-ED
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 250 participants (estimated)
- Lead sponsor
- Aaron KeshenUniversity, hospital or other
- Collaborators
- Queen Elizabeth II Health Sciences Centre Foundation
- Study start
- 4 Mar 2026 (actual)
- Primary completion
- May 2027 (estimated)
- Study completion
- May 2027 (estimated)
- First posted
- 6 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this interventional study is to evaluate the Treatment and Evaluation for After Metabolic Surgery with Eating Disorders (TEAM-ED) program, which combines streamlined access to screening, diagnostic assessment, and treatment with an interdisciplinary team approach to treatment planning, for managing disordered eating in adults who have recently had weight loss surgery in Nova Scotia. The main question it aims to answer is 'can an interdisciplinary program for identifying and managing disordered eating after weight loss surgery be implemented in Nova Scotia?
This study will determine the feasibility and impact of the TEAM-ED program by assessing the following objectives:
- Reach (how effectively the program engages the target population [post-weight loss surgery patients])
- Effectiveness (the extent of the program's impact on key clinical outcomes related to disordered eating and weight management)
- Adoption (the extent to which the program is adopted and accepted by clinicians)
- Implementation (how consistent program delivery is and factors impacting consistent delivery)
Participants will complete a disordered eating screening questionnaire online every 3 months after weight loss surgery until they reach 18-months post-surgery. Participants found to have disordered eating will be referred to the Nova Scotia Provincial Eating Disorder Service (NSEDPS) for standard disordered eating treatment (brief cognitive behavioral therapy [CBT-T]) plus treatment plan oversight by both weight loss surgery and eating disorder specialists. Standard outcome measures will be collected at baseline, during eating disorder treatment, post-treatment, and at follow-ups. Participants may also be asked to do a one-on-one research interview about their experiences with the program.
Study design
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| TEAM-ED Program | Experimental | Behavioral: Treatment and Evaluation for After Metabolic Surgery with Eating Disorders (TEAM-ED) Program |
Who may qualify
- Ages
- 19 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- ≥19 years old
- Between 3- and 18-months post-weight loss surgery.
- Able to complete English computer-based self-report questionnaires (with adequate accommodation, if necessary).
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Treatment and Evaluation for After Metabolic Surgery with Eating Disorders (TEAM-ED) ProgramA program that combines a) streamlined access to screening, diagnostic assessment, and treatment (brief cognitive behaviour therapy [CBT-T]), b) an interdisciplinary team approach to treatment planning, for managing disordered eating in patients post-weight loss surgery. | Behavioural | TEAM-ED Program |
Primary outcome
Screening Engagement Rate
Time frame: From the post-weight loss surgery timepoint when a participant is first enrolled in the screening procedure (3-, 6-, 9-, 12-, 15-, or 18-months) until 18-months post-surgery or until they screen positive for disordered eating.
Percentage of eligible patients (i.e., post-weight loss patients who are enrolled in the screening procedure) who complete the disordered eating screening measure (i.e., Loss of Control Over Eating Scale [LOCES]) at each timepoint (3-, 6-, 9-, 12-, 15-, and 18-month). To be calculated with the equation: [Actual # of LOCES completed at a timepoint] / [Total # of eligible patients who could have completed LOCES at that timepoint]
32 secondary outcomes
Screening Initiation Rate
Time frame: From 3- to 18-months post-weight loss surgery.
Proportion of eligible patients who screen positive for loss of control eating.
Time frame: From 3- to 18-months post-weight loss surgery.
Proportion of eligible patients who undergo a disordered eating diagnostic interview.
Time frame: From the post-weight loss surgery timepoint when a participant is first enrolled in the screening procedure (3-, 6-, 9-, 12-, 15-, or 18-months) until they screen positive for disordered eating.
Proportion of eligible patients who are diagnosed with disordered eating.
Time frame: From the post-weight loss surgery timepoint when a participant is first enrolled in the screening procedure (3-, 6-, 9-, 12-, 15-, or 18-months) until they screen positive for disordered eating.
Proportion of eligible patients who start disordered eating treatment.
Time frame: From the post-weight loss surgery timepoint when a participant is first enrolled in the screening procedure (3-, 6-, 9-, 12-, 15-, or 18-months) until they screen positive for disordered eating.
Change in disordered eating symptom frequency from baseline to post-treatment.
Time frame: From baseline to post-treatment (Week 10).
Change in disordered eating psychopathology severity from baseline to Week 4.
Time frame: From baseline to Week 4.
Change in disordered eating psychopathology severity from baseline to post-treatment (Week 10).
Time frame: From baseline to post-treatment (Week 10).
Change in disordered eating psychopathology severity from baseline to 1-month follow-up.
Time frame: From baseline to 1-month follow-up (i.e., 1 month after Week 10).
Change in disordered eating psychopathology severity from baseline to 3-month follow-up.
Time frame: From baseline to 3-month follow-up (i.e., 3 months after Week 10).
Change in anxiety symptom severity from baseline to Week 4.
Time frame: From baseline to Week 4.
Change in anxiety symptom severity from baseline to post-treatment (Week 10).
Time frame: From baseline to post-treatment (Week 10).
Change in anxiety symptom severity from baseline to 1-month follow-up.
Time frame: From baseline to 1-month follow-up (i.e., 1 month after Week 10).
Change in anxiety symptom severity from baseline to 3-month follow-up.
Time frame: From baseline to 3-month follow-up (i.e., 3 months after Week 10).
Change in depression symptom severity from baseline to Week 4.
Time frame: From baseline to Week 4.
Change in depression symptom severity from baseline to post-treatment (Week 10).
Time frame: From baseline to post-treatment (Week 10).
Change in depression symptom severity from baseline to 1-month follow-up.
Time frame: From baseline to 1-month follow-up (i.e., 1 month after Week 10).
Change in depression symptom severity from baseline to 3-month follow-up.
Time frame: From baseline to 3-month follow-up (i.e., 3 months after Week 10).
Change in psychosocial impairment from baseline to Week 4.
Time frame: From baseline to Week 4.
Change in psychosocial impairment from baseline to post-treatment (Week 10).
Time frame: From baseline to post-treatment (Week 10).
Change in psychosocial impairment from baseline to 1-month follow-up.
Time frame: From baseline to 1-month follow-up (i.e., 1 month after Week 10).
Change in psychosocial impairment from baseline to 3-month follow-up.
Time frame: From baseline to 3-month follow-up (i.e., 3 months after Week 10).
Change in weight from baseline to Week 4.
Time frame: From baseline to Week 4.
Change in weight from baseline to post-treatment (Week 10).
Time frame: From baseline to post-treatment (Week 10).
Change in weight from baseline to 1-month follow-up.
Time frame: From baseline to 1-month follow-up (i.e., 1 month after Week 10).
Change in weight from baseline to 3-month follow-up.
Time frame: From baseline to 3-month follow-up (i.e., 3 months after Week 10).
Treatment Non-Response Rate
Time frame: From baseline (Week 1) to post-treatment (Week 10).
Treatment Completion Rate
Time frame: From baseline to 3-month follow-up (i.e., 3 months after Week 10)
Program Dropout Rate
Time frame: From recruitment initiation (Month 0) to recruitment end (Month 24).
Acceptability of the TEAM-ED program to clinicians.
Time frame: At 12 and 18 months.
Adjunctive Pharmacotherapy Initiation Rate
Time frame: From baseline to 3-month follow-up.
Patient satisfaction with the TEAM-ED program.
Time frame: At 3-month follow-up (i.e., 3 months after Week 10).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Bariatric Surgery Patients
Not yet recruitingPhase 3
Safety and Analgesic Efficacy of the Biased μ-Opioid Receptor Agonist Tegileridine for Post-Operative Analgesia in Patients Undergoing Bariatric Surgery
Pain Management, Overweight , Obesity
Recruiting
Preoperative Oral Carbohydrate Loading and Gastrointestinal Recovery After Bariatric Surgery in Metabolic Syndrome
Metabolic Syndrome (MetS)
Recruiting
Impact of a Perioperative Physical Exercise and Respiratory Physiotherapy Program on the Patient Undergoing Bariatric Surgery
Bariatric Surgery and Physical Activity, Obesity/Therapy
RecruitingObservational study
Blood Collection Biorepository for Liver Disease Research
Non-Alcoholic Steatohepatitis(NASH), Hepatitis C
Recruiting
Identification of Pre-surgical Phenotypic Indicators Predictive of Quality of Life Trajectories in Obese Patients Following Bariatric Surgery
Obesity, Morbid, Obesity and Overweight
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Aaron Keshen, MD principal investigator
Nova Scotia Health Authority
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Treatment and Evaluation for After Metabolic Surgery with Eating Disorders (TEAM-ED) Program in people with Bariatric Surgery Patients and Disordered Eating Behaviors, run by Aaron Keshen at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 20 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Aaron Keshen, MD (902-449-8228, aaron.keshen@nshealth.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Screening Engagement Rate (time frame: From the post-weight loss surgery timepoint when a participant is first enrolled in the screening procedure (3-, 6-, 9-, 12-, 15-, or 18-months) until 18-months post-surgery or until they screen positive for disordered eating.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2026.